Reading view

There are new articles available, click to refresh the page.

VC's healthcare predictions for 2025: more M&A, fierce competition in AI, and a health insurance shake-up under Trump

A stethoscope wrapped around a white piggy bank on a blue background (Healthcare funding)
Investors are watching for a pickup in healthcare M&A deals in 2025.

Nudphon Phuengsuwan/Getty Images

  • After a slower-than-anticipated year for healthcare funding, investors expect sunnier skies in 2025.
  • 13 VCs from firms like ICONIQ Growth and AlleyCorp share their predictions for digital healthcare next year.
  • They expect more M&A, funding for AI agents and clinical decision support, and Medicare shake-ups.

The healthtech sector will see more private-equity-backed M&A and a fierce battle between AI-scribing startups next year, according to thirteen investors in the healthcare VC market.

At the beginning of the year, healthcare venture capital appeared poised for a rebound. Investors hoping to do deals again after a two-year funding drought watched as healthcare startups flooded back to the market to grab more cash.

Those VCs raced to break out their checkbooks for hot new AI startups in the first quarter, from scribing startups like Abridge to automated prior authorization players like Cohere Health.

A confluence of macroeconomic factors — from still-high interest rates to fundraising struggles for venture firms to the uncertainty of a looming presidential election — dampened the anticipated resurgence. 2024's funding appears to be, at best, on pace with 2023 levels, with $8.2 billion raised by US digital health startups in the first three quarters of this year compared to $8.6 billion through Q3 2023, per Rock Health.

Now, with interest rates expected to drop and a new administration on the way, VCs are anticipating sunnier skies in 2025.

A pickup in healthcare M&A and IPOs

After a slow year for healthcare M&A, investors want to see more deals in 2025.

With interest rates expected to come down — and investors facing pressure to deploy capital — private equity buyers should be more active in 2025, said .406 Ventures managing director Liam Donohue.

And Flare Capital Partners' Parth Desai said he's already seeing private-equity-backed healthcare companies looking to buy smaller startups. Their goal, as he understands it, is to make tuck-in acquisitions in 2025 that improve their growth stories as they look ahead to potential IPOs in 2026.

"Maybe they're not phenomenal outcomes, but at the end of the day, they'll create some liquidity," Desai said of those acquisitions. "I expect that to be one of the first exit windows starting to manifest in 2025."

Investors were hopeful but unsure that the IPO window would meaningfully reopen for digital health startups in 2025, despite startups like Hinge Health and Omada Health signaling their intentions to test the public markets.

Venrock partner Bryan Roberts said he expects the healthcare IPO market to remain relatively quiet. LRV Health managing partner Keith Figlioli suggested we won't see IPO activity kick off until the second half of the year after other exit windows open.

VCs said they're mostly looking for smaller deals next year, from mergers of equals to asset sales. Figlioli and Foreground Capital partner Alice Zheng said we'll see even more consolidation and shutdowns in digital health next year as startups run out of cash.

"Investors will have to make tough decisions on their portfolio companies," Zheng said. "We want to support all of them, but we can't indefinitely."

Alice Zheng
Alice Zheng, a partner at Foreground Capital, expects to see more consolidation and shutdowns as investors make tough decisions about their digital health portfolios.

Foreground Capital

Healthcare AI competition will get fierce

Healthcare startups using AI for administrative tasks were easily the hottest area of healthcare AI investment in 2024. Investors think the crop of well-funded competitors will face increasing pressures next year to expand their product lines.

ICONIQ Growth principal Sruthi Ramaswami said she expects the group of AI scribing startups that landed big funding rounds this year, from Abridge to Ambience Healthcare to Suki, to scale significantly next year using the fresh cash as hospitals scramble for solutions to the healthcare staffing shortage.

As these startups scale, however, they'll face pressure to expand beyond ambient scribing into other product lines, like using AI for medical coding and billing, said Kindred Ventures managing partner Kanyi Maqubela. Scribing technology could become a commodity sooner than later, with many providers trying free off-the-shelf scribing software rather than contracting with startups, Maqubela said.

"It'll be a race to who can start to build other services and build more of an ecosystem for their provider customers," he said.

Kindred Ventures Kanyi Maqubela, Steve Jang
Kindred Ventures general partner Kanyi Maqubela thinks medical scribe startups will have to race to find new product lines against commoditization.

Kindred Ventures

Some AI startups, like Abridge, have already been vocal about their plans to expand into areas like coding or clinical decision support. The best-funded AI scribing startups may be able to acquire smaller startups to add those capabilities, but other scribing companies will be more likely to get bought out, Maqubela said.

Flare Capital Partners' Desai suggested that healthcare companies already focused on RCM will try to pick up scribing solutions as the tech becomes a must-have for hospitals. He pointed to Commure's $139 million take-private acquisition of Augmedix in July.

Ramaswami said that demonstrating a high return on investment would be critical for these startups as hospitals pick their favorites among various AI pilots.

Sruthi Ramaswami, Iconiq Growth
Sruthi Ramaswami

Iconiq Growth

Health insurance in flux in Trump's second term

While many VCs quietly celebrated the potential for more M&A and IPOs in 2025 following Trump's election in November, the incoming administration could bring some big shake-ups for healthcare markets.

Trump could move to boost private health insurers, including Medicare Advantage plans, in his second term, Venrock's Roberts said. That could be a boon for young insurers like Devoted Health and Alignment Healthcare fighting for Medicare Advantage market share, as well as startups contracting with insurers to improve healthcare payment processes.

He suggested the new administration may even roll back changes made in the Center for Medicare and Medicaid Services' latest reimbursement model for Medicare, which went into effect this year and resulted in lower payments for many Medicare Advantage plans in the agency's attempt to improve payment accuracy.

Brenton Fargnoli, a general partner at AlleyCorp, said he expects to see health insurers respond to these risk adjustment changes and move to control higher-than-expected medical costs over the past year by launching a bevy of new value-based care partnerships in 2025 for specialties, including oncology, cardiology, and musculoskeletal care.

A photo of investor Brenton Fargnoli smiling, wearing a white t-shirt against a white backgorund
Brenton Fargnoli, a general partner at AlleyCorp, thinks insurers will launch a bevy of value-based care partnerships in 2025 for high-cost specialties.

AlleyCorp

Some healthcare experts are also concerned that the federal government could cut funding for Medicaid plans. These changes could force states to scramble for new strategies and potentially new partnerships to control healthcare costs for their Medicaid populations.

"If there is a significant shift in direction at the federal level, I think you're going to see certain states do much more than they have in the past to try to continue to address health disparities," said Jason Robart, cofounder and managing partner of Seae Ventures. "As it happens, that creates opportunities for private companies to leverage their innovative solutions to address the need."

Similarly, Muse Capital founding partner Rachel Springate said that while investors in reproductive health startups will be closely watching state-level regulatory changes that could impact their portfolio companies, those startups could see surges in consumer demand as founders step up to fill gaps in reproductive care access.

Some of the Trump administration's proposed moves could stunt progress for health and biotech startups by stalling regulatory oversight. Robert F. Kennedy Jr., Trump's pick to lead Health and Human Services, has said he wants to overhaul federal health agencies, including the Food and Drug Administration and the National Institutes of Health. Marissa Moore, a principal at OMERS Ventures, said the promised audits and restructuring efforts could lead to major delays in critical NIH research and FDA approvals of new drugs and medical devices.

Rachel Springate, Muse Capital
Rachel Springate, founding partner at Muse Capital, thinks reproductive health startups could see surges in consumer demand as founders step up to fill gaps in care access.

Muse Capital

What's hot in AI beyond scribes

In 2025, AI will be an expectation in healthcare startup pitches, not an exception, said Erica Murdoch, managing director at Unseen Capital. Startups have pivoted to position AI as a tool for improved efficiency rather than as their focal point — and any digital health startups not using AI, in turn, will need a good reason for it.

With that understanding, investors expect to see plenty more funding for healthcare AI in 2025. While many tools made headlines this year for their ability to automate certain parts of healthcare administration, .406 Ventures' Donohue and OMERS Ventures' Moore said they expect to see an explosion of AI agents in healthcare that can manage these processes autonomously.

Investors remain largely bullish about healthcare AI for administrative tasks over other use cases, but some think startups using the tech for aspects of patient diagnosis and treatment will pick up steam next year.

"We will begin to see a few true clinical decision support use cases come to light, and more pilots will begin to test the augmentation of clinicians and the support they truly need to deliver high quality, safe care," said LRV Health's Figlioli. He hinted the market will see some related funding announcements in early 2025.

Moore said she's also expecting to see more investments for AI-driven mental health services beyond traditional cognitive behavioral therapy models — "for example, just today I got pitched 'the world's first AI hypnotherapist."

Dan Mendelson, the CEO of JPMorgan's healthcare fund Morgan Health, said he's watching care navigation startups from Included Health to Transcarent to Morgan Health's portfolio company Personify that are now working to improve the employee experience with AI. The goal, he says, is for an employee to query the startup's wraparound solution and be directed to the right benefit via its AI, a capability he says he hasn't yet seen deployed at scale.

"These companies are racing to deploy their data and train their models, and we'd love to see a viable product in this area," he said.

Read the original article on Business Insider

VCs say digital agents, 'crypto mania,' and a torrent of liquidity are the tech trends to watch in 2025

Photo illustration of a robot hand with cash.

zentilia/Getty Images; Jenny Chang-Rodriguez/BI

After three years of tense reductions, the skies are clearing over Silicon Valley, and startup investors seem broadly optimistic about a resurgence in tech dealmaking.

We asked venture capitalists at 35 firms like Andreessen Horowitz, Insight Partners, IVP, and Sapphire Ventures, to tell us what's hot and what's not in tech next year, how potential regulatory changes could rouse a sleepy exit market, and where artificial intelligence goes from here.

In 2025, venture capitalists expect a loosening of antitrust regulations under the new presidential administration. This could reignite acquisition activity by strategic buyers, which would allow funds to distribute proceeds from those deals to their own investors, or limited partners, and raise new funds to invest in the next generation of startups, said Brian Garrett, managing director at Crosscut Ventures.

In recent years, startups weren't the only ones facing a cash crunch. Established funds raised the lion's share of funding dollars, while many newish and boutique funds struggled to raise. A torrent of dealmaking, combined with Trump's return to the White House and an end to the political uncertainty, could mobilize investors in these funds who had been sitting on the sidelines to whip out their checkbooks, said Ivan Nikkhoo, a managing partner at Navigate Ventures.

"Uncertainty breeds defense, optimism breeds offense," said Matt Murphy, a partner at Menlo Ventures and early Anthropic investor. "We're going into a cycle where acquirers are feeling they need to play offense and startups feel like it's time to invest in leadership. And the IPO market is open for best-in-class assets."

From IPOs to robotaxis, these are the tech trends to watch in 2025, according to venture capitalists.

Infrastructure cools off, apps soar
A woman in colorful, fashionable clothing browsing on her phone
Young people can feel pressured to keep up with every fashion trend they see on social media.

pixdeluxe/Getty Images

Jai Das, president and partner at Sapphire Ventures: "A larger number of 'application layer' companies will have a breakout year with several crossing $100 million in revenues. I predict 50 companies will cross $50 million ARR while still growing 60%+, and at least 10 will hit $100 million ARR. A lot of these companies will be prosumer companies, but there will be several business application companies as well."

Ben Lerer, managing partner at Lerer Hippeau: "When you get the cost of compute going down as quickly as it has, and the number of options in terms of foundational models growing as it has, you end up with a really interesting time for the application layer to thrive. If you're a startup, you can go with the flavor of the month — not just a ChatGPT wrapper, or a Claude wrapper, or a Gemini wrapper, or you name it — but some combination of all of them to optimize functionality, results, and the cost of those results."

Lower rates kick the IPO market into gear
Man in a tuxedo sprays Champagne.

Uwe Krejci/Getty Images

Sofia Dolfe, partner at Index Ventures: "2025 is the year we will see the IPO market opening back up. There are already signs that this is on the horizon: we're seeing gradual recovery, rates have started to come down, and there are many later-stage companies with the financial profiles to go public."

Michael Yang, senior managing partner at Omers: "Two kinds of companies will go public as the IPO window opens back up next year. First, the truly great businesses that are really scaled and have forecastable growth and would've gone public earlier if the IPO market was more favorable, and second, companies that entered into structured financings with dirtier terms that need to go public for timing reasons."

Nima Wedlake, managing director at Thomvest Ventures: "The IPO market will remain closed for most tech companies, with a high bar for entry — $300 million-plus ARR, fast growth, and cash-flow breakeven or better."

As crypto prices surge, founders return to the drawing table
Coinbase CEO Brian Armstrong
Coinbase CEO Brian Armstrong.

Jason Armond/Los Angeles Times via Getty Images

Nihal Mehta, general partner at Eniac: "Guidance on what the regulations could be for crypto and AI would encourage founders to build productively within those areas."

Jai Das, president and partner at Sapphire Ventures: "The new administration is crypto-friendly, bringing with it an expected acceleration of crypto-based business models (especially those using stablecoins). I predict we'll have another crypto mania in 2025."

Some venture funds go belly-up
dead fish
A woman walks on a beach blanketed with dead sardines in Tolten, Temuco, Chile.

AP Photo/Felix Marquez

Wesley Chan, cofounder and managing partner at FPV Ventures: "In 2025, I predict a lot of contraction for VCs, except for top funds. We're still in a downturn. Some firms shut down, a lot of firms are not doing new deals, and you will see a lot of junior-mid level employees leave."

The great funding bifurcation continues
A hand holding several $100 bills, while two other hands grab at the money.

iStock, BI

Molly Alter, partner at Northzone: "The 'sexiest' deals will continue to raise at sky-high valuations, but for the rest of the pack, companies will need to show very specific metrics to command a strong valuation. There will be a great bifurcation into the 'haves' and the 'have-nots.'"

Don Butler, managing director at Thomvest Ventures: "Startup shutdowns will increase, particularly at the seed stage, as companies run out of cash. This will influence valuations, with investors likely focusing on startups that have shown resilience or achieved meaningful milestones."

Matt Murphy, partner at Menlo Ventures: "Valuations will rise as growth rates and market multiples recover, but many companies still might not grow back into their ZIRP valuations. People are over that and won't let it get in the way of pursuing opportunity. Valuations for GenAI companies will continue to be outliers based on any historical metrics."

Robotaxis cover new terrain
The interior of a Waymo driverless taxi is shown navigating down a Los Angeles street.

Mario Tama/Getty Images

Brian Walsh, head of Wind Ventures: "2025 will be the year that we enter the age of 'robo taxis' with, first, Waymo now well along its adoption S-curve in San Francisco and expanding quickly, and, second, Tesla favorably positioned with quickly maturing best-in-class autonomy technology (no human in the loop) and an existing large fleet to scale it."

Kasper Sage, managing partner at BMW i Ventures: "Autonomous fleet deployments will gain traction in controlled, high-density environments such as for applications like campus environments and logistics for heavy industries."

Trump policy heralds return of megadeals
Meta CEO Mark Zuckerberg
Mark Zuckerberg.

David Zalubowski/ AP Images

Aaron Jacobson, partner at NEA: "With the change of administration, I expect the return of mega M&A deals. We are going to see a 'WhatsApp' like $20 billion-plus M&A outcome for a leading AI company."

Michael Yang, senior managing partner at Omers: "Big Tech will be back at the M&A table with a new administration and regulatory regime in place. They've been quieter in recent times but should be chomping at the bit to capitalize on what is still a buyer's market."

Funding rounds become even more fluid
Letter blocks fly through the air

Catherine Falls Commercial/Getty Images

Sasha McKenzie and Van Jones, both deal leads at Wellington Access Ventures at Wellington Management: "The concept of letter rounds in VC is becoming more amorphous. We're seeing $30 million and $100 million seed rounds, raising questions about what seed even means anymore. The model is shifting towards evaluating how quickly founders can run and how disciplined they are with results, rather than hitting historically stated milestones (e.g., $1 million in revenue to raise a Series A). There will be more nuance in how VCs evaluate progress, focusing more on the operator and their ability to balance vision with execution, based on the capital they have."

Multi-agent systems take center stage
A robot hand over a human hand on a computer

iStock; Rebecca Zisser/BI

Aaron Jacobson, partner at NEA: "Chatbots are overhyped. Agents are under-hyped. Enterprises will move beyond the low-hanging fruit of 'GPT-wrappers' to deploy digital workers that can reason and take action to make a real business impact."

Praveen Akkiraju, managing director at Insight Partners: "If 2024 was the year of LLMs, we believe 2025 will be the year of agentic AI — where highly capable state-of-the-art reasoning LLMs are combined with orchestration frameworks like memory, tool calling, and user-in-the-loop processes to build AI agents that can address progressively complex business workflows."

Seema Amble, partner at Andreessen Horowitz: "In the short term, human workers will be the reviewer in the loop; in the future, as trust is established over time, I expect many data-derived actions will shift toward being entirely a set of narrowly defined task-driven agents."

S. Somasegar, managing director at Madrona: "The world where we each have a digital assistant that works with a collection of AI agents is probably five to ten years out. But having AI agents that can do specific tasks really, really well is happening sooner and I think we will see a ton of progress on this in 2025."

Tender offers grow for a selective group of companies
Elon Musk spaceX
Elon Musk SpaceX

Saul Martinez/Getty Images

Ravi Viswanathan, founder and managing partner at NewView Capital: "The venture secondaries market will continue to be an important source of liquidity — a trend we think is here to stay due to structural dynamics of the venture asset class."

Simon Wu, partner at Cathay Innovation: "The size of tender offers has grown from millions to billions as the desire to own top-performing names by mutual funds and VCs increases, thus allowing some of the best names to stay private longer. Tenders are likely to get bigger to a selective group of companies in tandem with a more active IPO market next year."

Industry-specific software takes over
Mark Bordo and his dog Riley have been going to work together since the beginning of the pandemic at Vetster, an online platform to connect people with vets.
Mark Bordo works alongside his dog Riley at Vetster, an online platform to connect people with vets.

Paige Taylor White/Toronto Star via Getty Images

Molly Alter, partner at Northzone: "Vertical SaaS will become more highly valued than ever, due to the increasing difficulty of differentiating a product in horizontal categories."

Cathy Gao, partner at Sapphire Ventures: "Vertical software will evolve rapidly as AI moves to the agentic phase, enabling end-to-end automation of complex, industry-specific workflows that were once beyond the reach of software. By pairing deep domain expertise with intelligent automation, vertical AI will unlock new use cases, deliver outsized ROI, and become table stakes for staying competitive."

Fintech roars back
Markets image of money being exchanged

blackred/Getty, PM Images/Getty, Tyler Le/BI

Alexa von Tobel, managing partner at Inspired Capital: "Given the new political climate, we, of course, expect to see less regulation across the board. I think we'll see acceleration in a few core categories, including fintech."

Marlon Nichols, managing partner at MaC Venture Capital: "Fintech is an area I'm excited to invest in, particularly fintech startups leveraging AI to create transformative personal finance tools."

Sydney Thomas, general partner at Symphonic Capital: "We are watching the regulatory environment towards fintech ease which has enabled massive speculation on what asset class will win. … This also means, many startups will be required to regulate themselves, which isn't always an easy thing to do."

Robots join society
A Tesla Optimus robot accepts a package in a doorway.
Optimus, also known as Tesla Bot.

Tesla

Claire Yun, investor at Piva Capital: "Generative AI will continue to accelerate and supercharge robotics; simultaneously, we will see a choke point in human labor as an aging domestic workforce and protectionist policies create a sharp supply and demand imbalance. The result will be a colorful Cambrian explosion of robots as they step in to fill this gap."

Bob Ma, partner at Wind Ventures: "Urban areas will have fleets of robots on sidewalks, while drones will manage suburban and rural deliveries. Enhanced speed, cost-efficiency, and sustainability will redefine retail and e-commerce, with regulations supporting wider adoption and innovation."

Yuri Lee, partner at IVP: "As AI advances enable robots to move from structured, repetitive tasks to more complex and dynamic real-world applications, we'll see rapid progress in robotic perception, manipulation, and decision-making capabilities."

Small language models rise in popularity
Microsoft hearts small language models
Microsoft CEO Satya Nadella.

Microsoft

Tasneem Dohadwala, partner at Excelestar Ventures: "Small language domain-specific models are starting to show more value. Instead of using vast swaths of the internet to train large models, these smaller models can be trained on specific datasets, such as medical journals, newspapers, or email collections. As a result, they are highly tailored and more accurate in reflecting a user's particular constraints and voice.

Michael Yang, senior managing partner at Omers: "If 2024 was the year of the LLMs, 2025 will be the year of small language models (SLMs) and proprietary data sets spawning the next generation of enterprise SaaS applications. Companies have realized that data in their midst can be harnessed in new and better ways than the 'structured workflow apps' of old and by leveraging targeted SLMs, they can do work differently, more efficiently."

Founders flock to private equity
Orlando Bravo
Thoma Bravo founder and managing partner Orlando Bravo.

Patrick T. Fallon/AFP via Getty Images

Brad Bernstein, managing partner at FTB Capital: "Despite the IPO market showing better performance in Q3'24 with proceeds already surpassing 2023 totals, structural issues like regulatory burdens and governance challenges still pose obstacles for small and mid-cap companies. Private equity markets are stepping in to fill the gap, with growth equity deals comprising a larger share of activity and providing opportunities for startups in high-growth sectors like insurtech and healthcare tech."

Jai Das, president and partner at Sapphire Partners: "With the new administration, I predict we will see an uptick in exits, and much more tech M&A activity. We'll also see PE firms buying up a lot of companies once boards and management teams realize these businesses won't be able to grow at 30% at scale and ultimately, IPO."

Open-source foundation models come for OpenAI and xAI's lunch
Elon Musk and Sam Altman
Elon Musk and Sam Altman

Michael M. Santiago/Getty, Nordin Catic/Getty, Tyler Le/BI

Aaron Jacobson, partner at NEA: "Open-source foundation models will close the gap with the leading proprietary models. On top of this we will see a significant shift away from pre-training models from scratch to fine tuning OSS models and distilling them to smaller models for faster performance."

Mo Jomaa, partner at CapitalG: "I predict that in 2025 we will continue to see open source technologies consume the infrastructure layer in software. We have seen this trend play out in several categories already, including data and analytics (which led to our investment in Databricks) and observability (which drove our investment in Grafana). Enterprises will continue to adopt open source because it helps them save money, avoid vendor lock-in, and shape the product roadmaps of the technologies that they procure."

Record deals and dollars flow to cyber and national security
Assaf Rappaport
Wiz cofounder and CEO Assaf Rappaport.

Kimberly White/Getty Images for TechCrunch

Andrew Schoen, partner at NEA: "We will see a surge of investment into technologies critical to restarting the US industrial base and enhancing national security. A record number of deals and dollars will go into AI, automation, cybersecurity, and frontier technology serving manufacturing, supply chain, and defense markets."

Jake Seid, general partner at Ballistic Ventures: "Over the next 18 months, we're going to see a lot more cybersecurity exits. While this may include an uptick in M&A activity, I expect we'll see cybersecurity companies go public in 2025 and in the first half of 2026 given how large the market for cyber products has become."

Trump's tech advisors bend his ear
David Sacks at the RNC
Trump's AI and crypto Czar David Sacks.

Tom Williams/CQ-Roll Call, Inc via Getty Images

Samir Kumar, general partner at Touring Capital: "We should expect a lot less regulatory headwinds in 2025 for AI given David Sacks will be the AI and crypto czar for the new administration. This is likely to even result in the repeal of President Biden's executive order on AI."

Francesco Ricciuti, associate at Runa Capital: "In the US, Trump is bringing prominent people from the startup and VC world in the government, and I wouldn't be surprised if the regulatory landscape will evolve towards entrepreneurship and technology."

Read the original article on Business Insider

Halle Tecco doesn't want to be your infertility influencer

Photo collage featuring Halle Tecco

Halle Tecco, Tyler Le/BI

For the past decade, Rock Health cofounder and prolific startup investor Halle Tecco has made her name as a voice for the voiceless in fertility care.

She founded fertility e-commerce startup Natalist in 2019 and egg freezing and donation startup Cofertility in 2022. She bet early on several fertility startups like unicorn Kindbody and healthcare provider Tia. She espoused radical transparency about her previous struggles to have a child.

While she raised funding to help other people get pregnant, though, Tecco's battles with infertility continued. She suffered eleven miscarriages, including losing twins at 17 weeks pregnant.

Now, she's taking a huge step back from the industry she helped cement.

"People expect me to continue that narrative. But I've moved on, and I don't want to continue talking about it," she told Business Insider. "I'm not trying to be an infertility influencer."

As she built businesses that aimed to give women control in their fertility journeys, Tecco struggled with a lack of control over her own. Behind closed doors, her dogged optimism clashed with grief and frustration. Her therapist told her, "This is you getting PTSD treatment while still at war."

Today, Tecco is done making new fertility bets. She wants to return to what got her excited about digital health in the first place — encouraging new and exciting ideas in a sluggish industry.

She's writing a book about what to expect when innovating in healthcare. She started teaching a course at Harvard Medical School this year about the complex network of stakeholders involved in healthcare entrepreneurship. She co-hosts the digital health podcast The Heart of Healthcare, and she sits on the boards of healthcare benefits company Collective Health and Cofertility.

She'll continue to support the women's health companies she's invested in. But as far as she's concerned, the fertility-centered chapter of her life is closed.

"I'm a healthcare investor, not a fertility investor. And I want to get back to that," she said.

Halle Tecco stands in front of a building at Harvard Medical School.
Tecco teaches courses on healthcare innovation at Harvard Medical School and Columbia University.

Halle Tecco


When Tecco went to Harvard Business School to get her MBA in 2009, she was already interested in healthcare innovation. But it was her time at Apple, where she spent the following summer working on healthcare offerings in the tech giant's app store, that brought her frustrations with the industry to a head.

"There's so much money in healthcare, and such a big opportunity to improve healthcare. Why is nobody building fun, useful things over here?" she recalls thinking.

Returning to business school for her second year, Tecco reconnected with classmate Nate Gross as he was getting his clinician networking startup Doximity, now a publicly traded company, off the ground. Together, they began an independent study about how to get entrepreneurs to bring fresh ideas and technologies to healthcare.

From that study, Rock Health was born — named for the many hours Tecco and Gross spent in front of a whiteboard in Harvard's Rock Center for Entrepreneurship.

Tecco and Gross started Rock Health in 2010 as an accelerator program at a time when few vertical-focused startup accelerators existed. Y Combinator and Techstars both launched about five years earlier to supercharge seed-stage tech startups with venture funding and expert guidance. Rock Health offered founders the chance to do the same in healthcare, with backing from VC firms like Accel Partners and NEA plus companies like Microsoft and Nike.

The firm has made some impressive investments through its venture fund, including in Waystar and Tempus AI, which both went public in 2024; Omada Health, which appears to be eyeing an IPO in 2025; and Lyra Health, which last raised capital at a nearly $5.6 billion valuation in 2022.

Gross and Tecco both attested that they were told "no" many, many times during Rock Health's creation. They faced plenty of pushback from longtime healthcare builders and investors who rejected their vision to bring more tech into the industry.

Those dismissals only strengthened Tecco's resolve.

"I made the promise that I will never be the cranky old guard. There's no use in it," Tecco said. "We need as many smart people helping us solve these problems as possible."

Halle Tecco Natalist
Tecco with Natalist chief medical officer Dr. Nazaneen Homaifar (left) and chief scientific officer Dr. Elizabeth Kane.

Natalist


After Tecco moved with her husband Cloudera cofounder Jeff Hammerbacher from San Francisco to New York City in 2016, she stepped away from Rock Health. She'd set her eyes on her next goal: building a family.

Getting pregnant turned out to be "a huge struggle," Tecco said, as she confronted the high costs of fertility treatments, a stunning lack of support and education, and no guarantees of pregnancy. She told Business Insider in 2019 that her own fertility journey was fraught with "a lot of misinformation, a lot of secrecy and shame."

Tecco's son was born through IVF in 2017 after four years of trying. Adamant about improving the fertility care experience for others, Tecco officially launched Natalist two years later to provide products and educational materials to people trying to get pregnant, from at-home ovulation tests to prenatal vitamins.

"It gave me a lot of satisfaction to support others in a way that I hadn't been supported," she said.

Tecco was early in the femtech investment wave, too, founding and backing fertility startups when few others did. She first invested in Kindbody's seed round in 2018; by some estimates, VC funding for women's health increased more than 300% between 2018 and 2023, even as healthcare funding slumped overall last year.

Natalist kit Halle Tecco
An early Natalist kit featuring prenatal vitamins, ovulation tests, pregnancy tests, and a guide to "Conception 101."

Natalist

While running Natalist, overseeing women's health strategy at Everly Health after Natalist was acquired, and then cofounding egg donation startup Cofertility, Tecco wanted to have a second child.

Getting pregnant a second time proved even more difficult. Tecco endured multiple unsuccessful rounds of IVF and eleven miscarriages, over nearly five years.

Throwing herself into her work did little to help her escape the heartbreak. Infertility and pregnancy, as she spent her spare time helping thousands of patients trying to conceive, were always on her mind. She wrestled with jealousy over other people's "miracle babies" as she waited desperately for her own.

Secondary infertility, the difficulty of having another child after a previous successful pregnancy, robbed Tecco of countless hours of her life and plenty of happiness. Miscarrying twins at 17 weeks pregnant was "the first time in my years where I didn't have a plan B," she wrote in a 2023 blog post.

She paused fertility treatments in the summer of 2022 to spend time with her family. After much reflection and therapy, she realized that "overcoming" her secondary infertility wouldn't mean having another child. It meant making peace with the idea that she never would.

"It was harder than I can explain to make that decision, especially if you're someone like me, where you're like, I want this thing, I'm going to get this thing," Tecco said.

But, she said, "I wanted to go into my 40s being really clear about my intentions of moving on."

Cofertility cofounders Halle Tecco, Lauren Makler, and Arielle Spiegel
Cofertility cofounders Tecco, Lauren Makler, and Arielle Spiegel.

Cofertility


Tecco entered healthcare not solely to invest in startups, or to build her own, but to help other aspiring healthcare entrepreneurs with fresh perspectives and technologies in clearing the industry's many hurdles. Now 41 years old, she wants to get back to that.

This year, she's been focused on writing a book with that very thesis, aiming to pass along her knowledge to the next generation of healthcare builders. She sees it as the natural next step up from her blog, where she's covered topics from the value of an MBA versus a master's degree in public health (both degrees that Tecco holds) to why a startup may not be venture-backable.

But, true to form, Tecco is juggling multiple other ventures as she writes. She's still recording The Heart of Healthcare podcast alongside industry experts including Bessemer Ventures Partners investor Steve Kraus and Fenwick & West startup lawyer Michael Esquivel. In her classes at Columbia University and Harvard Medical School, she's teaching and learning from hopeful healthcare innovators. She's stopped angel investing, choosing instead to focus on the startups she's already backed, but she's also invested her personal wealth in top venture funds, including Oak HC/FT, Seven Seven Six, and Union Square Ventures.

While Tecco's Cofertility cofounder Lauren Makler oversees day-to-day operations at the startup as CEO, Tecco remains deeply involved with the company's strategy and fundraising efforts as a board member. And Rock Health is "still running Halle's game plan," Gross said.

Makler and Gross both called Tecco's ambition "relentless."

"If Halle has conviction in something, she does not look back," Makler said. "And even having gone through what Halle has gone through, her conviction, effort, and enthusiasm for what we're doing has never wavered."

Halle Tecco in front of a computer preparing to virtually teach her class on healthcare innovation at Harvard Medical School.
Halle Tecco's virtual class at Harvard Medical School is called "Investing in Healthcare Innovation."

Halle Tecco

Tecco doesn't regret the many years she spent speaking out about infertility. She still feels strongly about the twisted financial incentives in fertility care and the stigmas associated with assisted reproduction, even though she's not a patient anymore.

"I don't want to add anything, but I wouldn't want to take anything away. It is still such an important part of my story," she said.

Tecco's book, which she hopes to publish in late 2025, will be infused with her personal experiences, which Tecco said she understands people are interested in. But at its core, she hopes it'll be the "welcome guide" she never got for people interested in healthcare innovation, as motivating as it is practical.

"My goal is that readers close the book, and they're like, let's do this," she said.

Read the original article on Business Insider

These 10 startups are using AI to disrupt healthcare payments as public outrage toward insurers mounts

The United Healthcare corporate headquarters on December 4, 2024 in Minnetonka, Minnesota.
The killing of United Healthcare CEO Brian Thompson is bringing patients' bitterness toward health insurers to the forefront.

Stephen Maturen/Getty Images

  • Health insurers are coming under fire for increasingly denying patient claims for medical care.
  • Investors are rushing to back startups using AI to automate the complex healthcare billing process.
  • These 10 startups are helping patients, providers, and insurers improve health payments with AI.

In the wake of the fatal shooting of UnitedHealthcare's CEO last week, public hostility toward health insurers has reached a boiling point.

After Brian Thompson was shot and killed in Manhattan on December 4, social media exploded in morbid celebration. Shell casings found at the scene of the crime reportedly showed the words "deny," "defend," and "depose," mirroring a phrase commonly used by insurance critics to describe tactics used by health plans to avoid paying claims. Suspect Luigi Mangione was arrested Monday with a note in his possession containing the line, "These parasites had it coming."

It's a reckoning for how healthcare in the US is paid for — or not paid for — as health insurers increasingly deny paying for patient care. UnitedHealthcare and other health insurers have come under fire in recent years for using algorithms to deny patient claims, particularly Medicare Advantage claims. Claim denial rates have been on the rise for more than a decade, and denied or delayed payments cost hospitals hundreds of billions of dollars a year.

A growing crop of startups think AI can help.

Investors are rushing to back startups using AI to help providers, patients, and health plans more accurately and efficiently pay for medical care.

These 10 startups are using AI to automate key parts of healthcare's complex billing process, from prior authorization to claims adjudication.

Alaffia Health
TJ Ademiluyi, CEO and cofounder of Alaffia Health.
TJ Ademiluyi, CEO and cofounder of Alaffia Health.

Alaffia Health

Founded: 2020

Total raised: $17.6 million

What it does: Alaffia Health works with health plans to automate time-consuming tasks in claims processing, such as reviewing large patient medical records and policy documents. The startup says its generative AI tools can help insurers supercharge their in-house clinical teams and reduce claims spending.

Alaffia Health last raised a $10 million Series A round in April led by FirstMark Capital.

Anomaly
Mike Desjadon, CEO of healthcare startup Anomaly.
Mike Desjadon, CEO of Anomaly.

Mike Desjadon

Founded: 2020

Total raised: $30 million

What it does: Anomaly uses machine learning to parse health insurers' policies and historical claims data to help clinicians predict and prevent claims denials. The startup was incubated by Redesign Health and has raised money from investors like RRE Ventures and Madrona.

Anterior
Anterior cofounders Tahseen Omar, COO, and Dr. Abdel Mahmoud, CEO.
Anterior cofounders Tahseen Omar, COO, and Dr. Abdel Mahmoud, CEO.

Anterior

Founded: 2023

Total raised: $23 million

What it does: Anterior provides tech to clinicians working inside health insurers to automate prior authorizations for covered medical care. The startup raised a $20 million Series A led by NEA in June. It's also backed by Sequoia Capital and Microsoft AI head Mustafa Suleyman.

Claimable
Claimable team: Zach Veigulis, Chief AI Officer; Alicia Graham, Chief Operating Officer; Warris Bokhari, CEO.
Claimable's chief AI officer Zach Veigulis, COO Alicia Graham, and CEO Warris Bokhari.

Claimable

Founded: 2023

Total raised: Undisclosed

What it does: Claimable launched in October to assist patients in creating appeal letters for denied medical claims. Its platform analyzes a range of data, including clinical research, insurer policies, and existing appeals data, to generate a personalized letter for $40.

The startup last raised a seed round from Walkabout Ventures, Humanrace Capital, and other investors in March. It's also part of Nvidia's startup accelerator program Inception.

Cofactor AI
Adi Tantravahi, Cofactor AI cofounder and CEO.
Adi Tantravahi, Cofactor AI cofounder and CEO.

Cofactor AI

Founded: 2023

Total raised: $4 million

What it does: Cofactor AI's platform analyzes information, including medical records, insurer policies, and claims data, to help hospitals appeal claims denials. The startup announced a $4 million seed round led by Drive Capital in November.

Cohere Health
Cohere Health CEO Siva Namasivayam
Cohere Health CEO Siva Namasivayam.

Cohere Health

Founded: 2019

Total raised: $106 million

What it does: Cohere Health contracts with health plans like Humana and Geisinger to automate prior authorizations for medical care. The startup claims its tech can reduce the number of unnecessary prior authorization denials to help patients get the care they need faster. Cohere Health last raised a $50 million Series B extension in February led by Deerfield Management.

Humata Health
Humata Health founder and CEO Dr. Jeremy Friese.
Humata Health founder and CEO Dr. Jeremy Friese.

Humata Health

Founded: 2023

Total raised: $25 million

What it does: Humata Health works with hospitals to automate the collection of documents included in requests for prior authorizations sent to insurers and flag likely denials. The startup raised a $25 million Series A in June, led by LRV Health and the Blue Venture Fund.

Dr. Jeremy Friese started Humata Health after serving as the president of health AI startup Olive, which shut down last year after selling its prior authorization business to Humata.

Goodbill
Goodbill cofounders: Patrick Haig, CEO, and 
Ian Sefferman, CTO
Goodbill cofounders Patrick Haig, CEO, and Ian Sefferman, CTO.

Goodbill

Founded: 2021

Total raised: $5.3 million

What it does: Goodbill works with patients and employers to reduce medical costs by cross-referencing medical records with incoming hospital bills to identify potential errors and overcharges. The startup last raised a $2 million funding round in March from Founders' Co-op, Maveron, and Liquid 2 Ventures.

Guardian AI

Founded: 2024

Total raised: Undisclosed

What it does: Guardian AI provides hospitals and physician groups with tools to analyze insurance reimbursement patterns and automate the handling of unpaid medical claims and denials. The startup was part of YCombinator's summer 2024 cohort; its founders previously worked on Palantir's AI revenue cycle management programs for hospitals.

Thoughtful AI
Thoughtful AI's leadership team: Dan Parsons, cofounder and chief product officer; Alex Zekoff, cofounder and CEO; and Chris Singleton, VP of automation.
Dan Parsons, Thoughtful AI cofounder and chief product officer; Alex Zekoff, cofounder and CEO; and Chris Singleton, VP of automation.

Thoughtful AI

Founded: 2020

Total raised: $40 million

What it does: The startup's AI agents help healthcare clinics process medical claims, check patient insurance coverage, and record payments. Thoughtful AI last raised a $20 million Series A in July, led by Drive Capital.

Read the original article on Business Insider

Scoop: Particle Health lands $10 million in funding after lobbing antitrust lawsuit against medical records giant Epic

Particle Health's booth at the Vive conference in 2024.
Particle Health has been embroiled in a heated battle with EHR giant Epic Systems since March.

Particle Health

  • Particle Health has raised $10 million from its existing investors, Business Insider has learned.
  • The raise comes shortly after the startup filed an antitrust lawsuit against EHR giant Epic Systems.
  • Particle has been embroiled in a monthslong dispute against Epic over patient data sharing.

Healthcare startup Particle Health has been battling electronic health records giant Epic Systems all year. Now, the startup just raised some extra cash to add fuel to the fire.

The startup has raised an additional $10 million from its existing investors, three sources with knowledge of the raise told Business Insider.

The raise comes three months after Particle Health filed an antitrust lawsuit against Epic, alleging Epic has been stifling competition in the emerging "payer platform" market.

Particle Health, founded in 2018, acts as a middleman between electronic health records systems like Epic and healthcare companies, drawing patient healthcare information from the EHR for use by providers and digital health players. It's backed by venture firms like Menlo Ventures, Canvas Ventures, and Pruven Capital, and last raised a $25 million Series B round in 2022.

The $10 million financing, which included all of Particle's major investors, intends to give the company additional runway for its next phase of growth, according to one person with knowledge.

The cash won't be used for Particle's antitrust lawsuit against Epic, because Particle itself isn't paying for the lawsuit, per two sources. Those people didn't share how exactly the lawsuit is being funded.

The lawsuit is the latest action in a complex, monthslong dispute between Epic and Particle.

Last year, Particle launched a payer platform to provide health plans with data aggregation capabilities for tasks like analytics and claims processing. Epic released its own payer platform in 2021.

In March, Epic filed a formal dispute with Carequality, the data interoperability network that both Epic and Particle Health use to access and exchange patient information for their payer platforms. Epic alleged that some of Particle Health's customers were using Carequality to access patient data for non-treatment purposes, potentially violating HIPAA. The EHR company then cut off data requests from those Particle Health customers.

As part of Carequality's review process, which reached a final resolution in October, Particle terminated its contracts with two of the customers in question and agreed to obtain written documentation from a third customer demonstrating appropriate use of Carequality's platform. Epic also agreed to revisit its own policies for determining whether an organization is using data for treatment.

But Particle's September lawsuit, filed in the Southern District of New York, doubles back. The suit alleges that Epic used its market dominance to hinder Particle's business by "coercing" Particle's customers, including both its healthcare provider customers and its payer customers, to cut ties with Particle. The lawsuit claims Epic cut off Particle customers' access to medical records stored in Epic's software, and told companies it would resume that access only if they stopped using Particle's payer platform.

Those actions and others by Epic, Particle's lawsuit claims, have led many Particle customers to drop their contracts and deter prospective customers, leading to a meaningful revenue loss for Particle.

Particle's lawsuit hinges on Epic's so-called monopoly as the nation's top EHR provider. KLAS research shows Epic covers over half of all hospital beds in US acute care centers; its closest competitor, Oracle Health, covers about 24%.

In turn, Epic sent a letter to the New York court in October asking the judge to throw out the suit. The company said the lawsuit "is Particle's attempt to distract from the public reckoning stemming from Particle's customers violating patient privacy."

Read the original article on Business Insider

Meet 45 rising stars of the venture capital industry who stood out in 2024

Jon Chu, Caroline Fiegel, Deedy Das, and Iris Sun.
From left to right: Jon Chu, Caroline Fiegel, Deedy Das, and Iris Sun.

Khosla Ventures; Salesforce Ventures; Menlo Ventures; 500 Global; Business Insider

  • We asked our readers and top VCs to name the best up-and-coming investors of 2024.
  • These VCs come from big and small firms and invest in startups across all sectors and stages.
  • These 45 venture capitalists are the names to keep on your radar in 2025 and beyond.

Over the last two years, artificial intelligence has exploded into public consciousness, leading to a boom in new startup creation and an antidote to an otherwise sleepy VC investing landscape.

The trend is creating more opportunities than ever for early-career investors to shine when it comes to helping source big deals — or even being the one to write the check.

Every year, Business Insider asks top investors to name the most promising young VCs in their networks. BI also asked the general public, as well as previous rising stars, who they thought should make the cut.

The investors selected to be our 2024 rising stars of venture capital come from a wide array of backgrounds and range from associates to founding partners at their funds, and we also threw in a few picks of our own based on the investor performance throughout this year.

Unsurprisingly, many young VCs are making a name for themselves by betting on hot AI startups. But BI's list also includes investors specializing in healthcare, defense tech, climate tech, and other industries.

Scroll to see 2024's rising stars of venture capital, organized alphabetically by the investor's name.

Daniel Aronovitz, Insight Partners
Daniel Aronovitz, Insight Partners
Daniel Aronovitz

Insight Partners

Over nearly a decade at Insight, Aronovitz has risen from analyst to principal, helping lead investments in Own Company, which Salesforce acquired, and Run:ai, which Nvidia bought. He looks for high-growth B2B SaaS companies in cybersecurity, infrastructure software, and vertical AI. Investments typically span Series A to Series D, with check sizes ranging from $5 million to $500 million.

In 2019, Aronovitz helped open the firm's office in Tel Aviv, Israel, where he lives with his family.

"I draw on years of software investing and pattern recognition to help founders navigate the challenges of scaling internationally," he said.

Casey Aylward, Accel
Casey Aylward, Accel
Casey Aylward

Accel

Aylward joined Accel in 2022. Since then, she has established herself as a go-to early-stage, open-source investor, continuing a firm tradition of early investments in companies like Cloudera, Sentry, and Vercel. She led Accel's seed investments in competitive deals, including VoidZero, founded and led by Evan You, the creator of widely adopted projects in the JavaScript ecosystem, and Astral, a startup building developer tools for the Python ecosystem.

This fall, she also helped organize the first CUDA Mode Hackathon alongside Nvidia and PyTorch, an open-source deep learning framework, attended by hundreds of developers.

Before Accel, Aylward worked at Costanoa Ventures, an early-stage enterprise fund, and was a software engineer at Pinterest, joining through the acquisition of the Accel-backed company URX.

Julien Barber, Emerson Collective
Julien Barber
Julien Barber

Emerson Collective

Climate tech investor Barber advises founders to "go deep" on a topic. He's done that himself as a venture investor at Emerson Collective, where he focuses on backing companies that use technology to break down barriers to a clean economy.

Specifically, he focuses on the hardware solutions needed to decarbonize the economy, such as nuclear fusion, energy storage, and other physical solutions in the energy, industrial, and transportation sectors. This year, Barber helped the firm invest in several clean energy startups, including Antora Energy, Xcimer Energy, and Zap Energy.

Before joining Emerson Collective, Barber completed his graduate program in Mechanical Engineering at MIT's Plasma Science and Fusion Center (PSFC) where he specialized in studying nuclear fusion technology. He also co-founded Commons, a carbon-tech start-up, and advises companies on corporate climate strategy.

Maggie Basta, Scale Venture Partners
Maggie Basta Scale Venture Partners
Maggie Basta

Scale Venture Partners

Basta was promoted to Vice President at Scale Venture Partners, where she focuses on AI infrastructure and developer tools. This past year, she sourced Scale's investments in Galileo, Cortex, Lumos, and QA Wolf. Scale led a $45 million Series B round in generative AI security and monitoring startup Galileo.

Basta is part of a growing number of technically trained VCs with deep expertise in AI and machine learning. Before Scale, Maggie worked as an ML engineer at QuantCo, building AI technology for algorithmic pricing and fraud detection. Her prior academic research focused on Deep Learning.

Basta, formerly a Harvard collegiate soccer player, has authored several key pieces on building and investing in AI infrastructure.

Lori Berenberg, Bloomberg Beta
Lori Berenberg, Bloomberg Beta
Lori Berenberg

Bloomberg Beta

Berenberg has made herself a staple of the New York City tech scene by organizing regular community events, including parties at NY Tech Week and her series of tech breakfasts.

"Venture is one of those rare careers you can start before getting the job," she said. "Build your network, explore your city's startup scene, meet founders, and practice evaluating live deals."

A former product manager, Berenberg joined Bloomberg Beta in 2022 and focuses on pre-seed and seed-stage investments in the future of workspace. Her portfolio includes the lawyer time-tracking platform Ajax and the community-hiring platform Twill. Berenberg earned her undergraduate degree from New York University's Stern School of Business.

Morgan Blumberg, M13
Morgan Blumberg, M13
Morgan Blumberg

M13

Blumberg joined the venture capital world in 2021, and she's since made a big impact on M13's portfolio. As a principal at the early-stage tech-focused firm, she helps lead M13's AI strategy and has sourced or led five of its most competitive AI investments in the past year, including its investments in Norm AI's $11 million seed round, led by Coatue, and RadiantGraph's $11 million Series A, led by M13.

She currently supports 11 of the firm's portfolio companies and sits on the boards of the freelance fintech startup WorkMade and the AI sales platform Lantern.

Blumberg previously worked in investment banking at Morgan Stanley. After leaving banking, she worked on Mike Bloomberg's 2020 presidential campaign and consulted for political media startups before joining M13. Her recent investments have focused on AI applications for the future of work and healthcare.

Molly Bonakdarpour, Drive Capital
Molly Bonakdarpour, Drive Capital
Molly Bonakdarpour

Drive Capital

Bonakdarpour shapes healthcare strategy as a partner at the Columbus, Ohio-based Drive Capital. This year, she's invested in early-stage startups bringing AI to healthcare, including Droxi AI and Clarence Health. She also sits on the board of the insurtech startup Sidecar Health, which raised a $165 million Series D round in June.

She's supported portfolio companies to successful exits even as M&A has lagged, including the Japanese food producer Ajinomoto's acquisition of Forge Biologics, a biotech startup she helped incubate, for $620 million at the end of 2023.

Before becoming an investor, Bonakdarpour led commercial partnerships at the diabetes company Livongo and held analyst roles at 7wire Ventures and JPMorgan.

Vig Chandramouli, Oak HC/FT
Vig Chandramouli, Oak HC/FT
Vig Chandramouli

Oak HC/FT

Chandramouli first saw the limitations of a healthcare system growing up in South India, where his grandfather still runs a small clinic for patients who can't afford to go to the hospital or seek specialty care. Now, at Oak, he backs founders building for underserved patients who can't advocate themselves.

Chandramouli joined Oak in 2014 as one of the firm's earliest employees. He's since worked on 35 of Oak's 58 healthcare investments to date, from new company incubations to growth-stage deals. He has largely focused on investments in value-based care enablement, with a recent eye for startups using AI in healthcare.

Chandramouli helped incubate the generative AI startup Trovo Health, which emerged from stealth in April with $15 million in seed funding led by Oak. He also sits on the boards of startups including Trovo Health, the virtual-reality surgery company Osso VR, and the healthcare training platform Stepful.

Sherry Chao, GV
Sherry Chao, GV
Sherry Chao

GV

Chao brings a scientific background to her role investing in life-sciences startups at GV. After finishing her MBA at Harvard Business School, Chao completed her doctorate in bioinformatics at Harvard, during which she worked in a cancer immunology lab at the Broad Insitute of MIT and Harvard. Collaborating with leading scientists there sharpened her eye for evaluating the science and market viability of GV's biotech investments.

Chao joined GV as a principal in 2021, and the firm promoted her to partner in January. She's worked on deals like GV's bets on the obesity biotech Metsera, the immunology startup Santa Ana Bio, and several companies still in stealth. Before securing her graduate degrees, Chao spent three years at Goldman Sachs as a private-equity analyst.

Jon Chu, Khosla Ventures
Jon Chu, Khosla Ventures
Jon Chu

Khosla Ventures

Chu is one of the investors leading Khosla's charge into AI. His focus on machine learning and its impact on enterprise infrastructure, applications, and developer tools has led the firm to make investments in high-potential startups such as Sakana, a research lab building a foundation model based on nature-inspired intelligence, and Loft Labs, a startup that virtualizes Kubernetes clusters that raised $24 million in funding in April.

Chu began his career as an engineer at Palantir and founded and sold a software-testing company, Koality, to Docker, where he ran Docker's enterprise group. More recently, he spent time at Opendoor, leading engineering for core machine learning, and at Facebook, overseeing engineering teams in both virtual reality and machine learning.

Zeeza Cole
Zeeza Cole
Zeeza Cole

Zeeza Cole

Cole recently wrapped up her time at Bain Capital Ventures, where she wrote checks for the clothing resale infrastructure startup Archive, the inventory-management platform Cofactr, and Arc, which is a digital bank for SaaS startups. Based in New York, she's focused on application software with a focus on industrials and vertical Saas.

Prior to her time at BCV, Cole was an associate at WeWork's creative fund and completed a stint in investment banking at Goldman Sachs. When it comes to founders, she says that the most important quality she looks for is earned insight.

"Whether that is domain expertise from years of working in the industry or simply becoming self-taught in a space where the founder is passionate, having a strong industry perspective is critical for building a future-facing company," she said.

Deedy Das, Menlo Ventures
Deedy Das
Deedy Das

Menlo Ventures

Although having only been at Menlo Ventures for less than a year, Das has already made his mark at the firm for his AI investing prowess. Das, who was previously on the founding team of hot AI search startup Glean, has helped launch the $100 million Anthology Fund in partnership with Anthropic (Menlo invested in the AI giant's $450 million series C round in 2023).

Deedy is one of only three team members (others include partners Matt Murray and Tim Tully) responsible for making investments out of the fund. Having held technical roles at Facebook and Google Previously, Das is also involved with the firm's investment in Pinecone and serves as an advisor to a number of AI startups including Perplexity.

Das is also a prolific contributor to AI and immigration thought leadership and has amassed over 100,000 followers on social media platform X.

On what he looks for in a founder: "Consistency. Focus is one of the most fleeting qualities in today's day and age. We're all distracted by the shiny new thing. Whether it comes from obsession, discipline or simply drive, being consistent is essential. A successful startup takes 7-10 years — that's a longer duration than most people have done anything."

James Detweiler, Felicis
James Detweiler
James Detweiler

Felicis

Detweiler found his way into venture by accident, rejecting roles in physics research and Wall Street trading and working at Silicon Valley Bank. In 2021, Detweiler bet big on AI investing, joining AI-focused fund Zetta Venture Partners. A year later, he joined Felicis with the intention of scaling out the firm's AI portfolio. Over the past few years, Detweiler has helped deploy around $100 million into 8 AI startups.

Detweiler, a physics major and Minecraft lover, has made several early bets on AI and machine learning startups, backing Shield AI. and Flower Labs. He also led Felicis' investment in Skild AI, a company building a foundation model for robotics. Shield AI was last valued at $2.7 billion, and Skild AI was last valued at $1.5 billion.

On what he looks for in a founder: "humility, grit/resilience, clear/secret narrative, talent magnet, fast learner/updates priors, high energy/rate of execution, extraordinary background/track record, and bonus points for expanding the scope of my imagination."

Dion Dong, Leadout Capital
Dion Dong, Leadout Capital
Dion Dong

Leadout Capital

Dong joined Leadout as a principal in 2022. Since joining the firm, which focuses on early-stage startups and helping companies find "founder-market fit," Dong has sourced seven investments, including Creatify, which makes video advertisements with AI, and the food-service sales platform First Bite.

Dong considers himself a generalist investor, though he says he's recently been focusing on the AI app layer. The University of California at Berkeley graduate has made over a dozen angel investments and completed stints at companies including Rippling and Laika. He said the latter experience had been crucial to his success on the VC side of things.

"Be more intentional about developing an investor mindset even before stepping into a full-time investor role, whether it's how you allocate your time, energy, resources, or relationships," he said. "Many skills will likely transfer when allocating capital if you excel at that."

Caroline Fiegel, Salesforce Ventures
Caroline Fiegel, Salesforce Ventures
Caroline Fiegel

Salesforce Ventures

At Salesforce Ventures, Fiegel manages investments for the firm's Slack Fund, which targets early-stage companies creating software and infrastructure meant to power the future of work. Since joining in 2022, Fiegel has helped define the fund's early-stage strategy and sourced and led investments such as Ensemble, a company dedicated to lowering barriers to state-of-the-art machine learning, and Tribble, which automates the "request for proposal" process.

Before she became an investor, Fiegel spent over three years leading product and go-to-market strategy at Quip, a horizontal productivity suite that Salesforce acquired in 2016.

Outside work, she hosts a recurring dinner series for female founders and operators — an effort she hopes to grow and formalize in the new year.

Samuel Garcia, Amplo
Samuel Garcia, Amplo
Samuel Garcia

Amplo

The Austin-based Garcia has been with Amplo for six years, starting out as an associate in 2018 and rising through the ranks before being promoted to partner in 2023. The fund focuses on seed and Series A investing, and Garcia considers himself a generalist investor, though he says he tends to gravitate toward the B2B SaaS, telecom, and legaltech sectors.

His investments include the legal-tech startup Steno, the AI-powered product-management software Axion Ray, and the digital network procurement startup Lightyear.

For Garcia, who graduated from the University of Texas at Austin as well as Harvard Law School, it's important to him that startup founders are experts in their chosen fields.

"I like to ask myself, 'If there was a graduate-level class on what this company does, could this CEO be a professor on it?'" he said.

C.C. Gong, Menlo Ventures
C.C. Gong, Menlo Ventures
C.C. Gong

Menlo Ventures

Gong has an unusually long résumé, especially for someone so young — product roles at Meta and Microsoft, an investor at Bain Capital Ventures, founder of her own video startup, and White House Presidential Innovation Fellow. She added another title to her résumé this year, joining Menlo as a principal. There, she focuses on pre-seed to Series C startups trying to revolutionize how people live, work, and play.

Gong prides herself on her hustle.

"I love breaking down doors for founders," she said. "Having been a founder myself I know how hard it is, and now as a VC my job is to make their job easier."

Jaya Gupta, Foundation Capital
Jaya Gupta, Foundation Capital
Jaya Gupta

Foundation Capital

Since joining Foundation in May 2023, Gupta has already made five seed-stage investments in the AI space, including the sales engineering company DocketAI. Based in San Francisco, Gupta previously completed a stint at the investment-banking firm RBC after graduating from Georgia Institute of Technology.

When it comes to finding success in the world of VC, Gupta said that it's important to find and trust your gut instinct.

"In this business, value for investors means sending relevant deals to the right people, and especially in early-stage investing it's more art than science," she said. "So, it's important to demonstrate you have the capability to identify potential breakthrough people and companies."

Fawzi Itani, Forerunner Ventures
Fawzi Itani, Forerunner Ventures
Fawzi Itani

Forerunner Ventures

Itani began his career at LinkedIn before starting a gaming research and advisory firm. In 2021, he joined Forerunner, which leads seed, Series A, and Series B rounds for consumer startups. Companies Itani works with include Fay Nutrition, which provides insurance-covered dietitians, and Feed, a retailer of healthcare supplements.

"I'd say my superpower has been identifying and engaging in markets that are on the precipice of change," Itani said. "I'm someone who can support our portfolio in any task no matter how big or small, unblocking them, brainstorming alongside them, and getting them in front of people they need to meet."

Tanay Jaipuria, Wing Venture Capital
Tanay Jaipuria, Wing Venture Capital
Tanay Jaipuria

Wing Venture Capital

As a partner at Wing, Jaipuria leads seed and Series A funding rounds in AI-powered applications and infrastructure. Since joining the firm in April 2022, Jaipuria has written checks for the AI social-media ad platform Sesame Labs and the time-tracking legaltech Billables.

Jaipuria, who is based in New York, says aspiring investors should fake it before they make it.

"Be in the flow — help founders with advice, connect them to investors, develop perspectives on sectors and share them online," he said. "You can practice most parts of the job without actually being in the job yet."

Prior to joining Wing, Jaipuria held roles across Big Tech, including product lead at Instagram, product manager at Facebook, and forward-deployed engineer at Palantir. He also spent time as a consultant at McKinsey. Jaipuria earned his undergraduate degree from Columbia University and also graduated from Harvard Business School.

Bryce Johnson, Primary Venture Partners
Bryce Johnson, Primary Venture Partners
Bryce Johnson

Primary Venture Partners

Johnson, based in New York, has been investing at Primary since 2023, and his focus areas include healthcare, fintech, and vertical SaaS. He's made bets on the AI construction startup Bobyard and the fund-management platform Maybern, in addition to a stealth healthtech company.

For Johnson, who graduated from Stanford University with a bachelor's degree in computer science focusing on AI, an important part of VC investing is identifying your strengths and building them into networking.

"VC is all about sharing your grand vision and then executing against the plan," he said. "A question I constantly ask myself as an investor is, 'Why would an incredible founder want to take a call with me when they have other investors knocking at their door?' If you can clearly answer that, doors will open."

Brannon Jones, AlleyCorp
Brannon Jones, AlleyCorp
Brannon Jones

AlleyCorp

After working as an engineer at SpaceX, Jones joined AlleyCorp in 2023 to invest in robotics, aerospace, advanced manufacturing, and energy transition technologies at the pre-seed through Series A levels.

"I've found that one of the most important values I'm able to bring to founders is a thorough understanding of deep tech, specifically its scalability throughout industries," Jones said. "The transition stage from concept to commercialization is notoriously challenging, and so that is where there can often be the most need from a founder's perspective."

Cynthia Kuo, IVP
Cynthia Kuo, IVP
Cynthia Kuo

IVP

After starting her career as a banker at Goldman Sachs and working in finance at Hopin, Kuo joined IVP in 2022. She has worked with two of the hottest startups of 2024, Perplexity and Glean. At IVP, Kuo focuses on AI applications, vertical software, and consumer platforms with check sizes ranging from $10 million to $50 million.

"My time at a startup — joining what was a lean finance team during a pivotal moment in the company's growth trajectory — gave me valuable insight into sustaining hypergrowth and, more importantly, tremendous empathy for founders and their teams," Kuo said. "That experience, combined with my background in finance, honed at Goldman Sachs, enriched my understanding of scaling."

Ashwin Lalendran, Moxxie Ventures
Ashwin Lalendran, Moxxie Ventures
Ashwin Lalendran

S72 Business Portraits/S72 Business Portraits

Lalendran, Moxxie's newest recruit, has designed and deployed computer vision and robotics systems across land, air, and sea. He worked on drones for the Air Force, shipped 3D vision software for Apple's mapping and self-driving-car projects, and led a team of engineers to scale the world's largest private-owned network of ocean sensors at Sofar Ocean.

In his latest role, Lalendran lends founders his operating expertise — having gone from napkin sketches to scaled deployment many times over — and his technical and commercial network. He specializes in regulated industries, whether manufacturing and mining or maritime and medicine.

Before Moxxie, Lalendran cut angel checks into Milu Health, a healthcare startup that raised a seed round of funding from Andreessen Horowitz, and Driver, a startup seeking to take the slog out of technical writing and recently announced $8 million in funding in a round led by GV.

Yuri Lee, IVP
Yuri Lee, IVP
Yuri Lee

IVP

IVP promoted Lee to partner in July, two years after she joined the firm from Morgan Stanley, where she worked on investment-banking deals like Affirm's and SentinelOne's 2021 IPOs. She's sourced and supported some of IVP's hottest deals this year, like its February investment in the AI-powered medical scribing startup Abridge's $150 million Series C. (The Information reported in October that Abridge was raising a fresh $250 million round at a $2.5 billion pre-money valuation, with IVP set to co-lead the deal alongside the tech investor Elad Gil.)

Lee makes investments across tech and healthcare. She serves on the board of the healthcare staffing startup Clipboard Health and helped IVP secure its investment in the hybrid care provider Accompany Health, which launched in January with a $56 million Series A. She also supports some of IVP's highest-value tech bets, including Discord; she cohosted Discord's B2B product launch event at the Game Developers Conference in March.

Beyond VC, Lee is an avid player and creator of video games — she developed the online multiplayer game "Arena of Kings," released in 2021. She was ranked in the top 1% of "League of Legends" players in the US for multiple years. She's lived in five countries, including South Korea, where she was born, Hungary, where she grew up, and now the United States.

Alex Lehman, Sapphire Ventures
Alex Lehman, Sapphire Ventures
Alex Lehman

Sapphire Ventures

Lehman rejoined Sapphire in 2022 after getting an MBA from the Stanford Graduate School of Business. She focuses on generative-AI startups at all layers, from infrastructure to application to large language models.

"As a member of the LGBTQIA+ community, I believe I'm transforming the industry while performing at the highest levels in an ecosystem across which people like me are not widely represented," Lehman said. "The founders I work with know that they are getting my honest take no matter what the context and that I am driven, hungry, and dedicated to working tirelessly towards their success."

Lindsey Li, Bessemer Venture Partners
Lindsey Li	Bessemer Venture Partners
Lindsey Li

Bessemer Venture Partners

Lindsey Li, who joined Bessemer Venture Partners in 2019 as an analyst, has sourced more than seven investments for the firm, including AI and software startups Seam AI and Rundoo.

This year, Li, who makes early-stage bets on startups across gaming and consumer, developer platforms, and crypto, was promoted to Vice President at Bessemer in 2024. She also spearheaded a study focused on AI's effect on developer tasks and contributed to Bessemer's annual State of the Cloud report.

Internally at Bessemer, she created and led the firm's Steel DAO initiative, which developed a platform for deal sourcing for crypto and web3. The DAO evaluated over 300 companies and resulted in four early-stage startups funded by Bessemer.

On what Li looks for in a founder: "Clarity of thought and vision. I find this is often predictive of other very important qualities, including being able to see the present clearly (i.e., hard-headed about the facts) and communicate in granular detail the steps between now and the future they envision."

Radhika Malik, Dell Technologies Capital
Radhika Malik	Dell Technologies Capital
Radhika Malik

Dell Technologies Capital

Malik was promoted from principal to partner at Dell Technologies' VC arm. She invests in AI, machine learning, cloud infrastructure, and deep tech. Her current investments include RunPod, Secuvy, SiLC, TheLoops, and several companies still in stealth mode. Malik sourced the seed investment in AI startup RunPod from an engineering subreddit; the startup raised $20 million from Dell and Intel Capital earlier this year.

A deeply technical software engineer, Malik was previously an investor with Samsung Catalyst Fund, Samsung's deep technology venture fund. Prior to becoming an investor, she worked as a software engineer and product manager at Microsoft and Amazon.

Malik's advice for any aspiring VCs: "Learn the fine balance between being analytical and data-driven and 'suspending disbelief' at the right time when you believe you may have come across a potential outlier. There are a million reasons to say no to any investment. Finding that one reason to say 'yes' takes being able to believe in a big vision that may be supported by very little data."

Abby Meyers, Bain Capital Ventures
Abby Meyers, Bain Capital Ventures
Abby Meyers

Bain Capital Ventures

Meyers says that in VC, it's crucial to do your homework.

"Coming into conversations informed, with interesting insights that can further the thinking of investors that you're interacting with, can demonstrate the type of value you'd bring as a member of their team," she said. "And, everything you learn while breaking in will help you do the job when you get there."

Meyers, who is based in New York, has been at Bain Capital Ventures since September 2022 and was promoted to principal in January 2024. She focuses on the application-software vertical, and her bets include the industrial workplace platform MaintainX, the legal-tech startup EvenUp, and the sales-focused Apollo.

Jesse Middleton, Flybridge Capital Partners
Jesse Middleton, Flybridge Capital Partners
Jesse Middleton

Flybridge Capital Partners

When Flybridge decided to take a big swing on New York's tech ecosystem with a dedicated fund, it named Middleton as the dealmaker in charge. He helped launch and now leads Next Wave NYC, a pre-seed venture fund, wholly owned by Flybridge, that invests in local entrepreneurs using artificial intelligence to build next-gen products.

Middleton is a general partner at Flybridge, having cut his teeth as an angel investor. He built up his network as an early employee at WeWork, where he built and supported a community of thousands of founders in WeWork Labs, the coworking company's take on a startup incubator.

His notable investments include Chief, the professional network for women in executive roles; Jackpocket, a lottery app that DraftKings purchased this year for $750 million; and Arcee.ai, an early-stage developer of small language models that announced two separate funding rounds this year.

Andrew Montgomery, Collaborative Fund
Andrew Montgomery, Collaborative Fund
Andrew Montgomery

Collaborative Fund

Montgomery has boomeranged back to the world of VC: He previously spent eight years at the seed investment firm Mesa Ventures but left in 2020 to be vice president of finance and strategy at the early-childhood edtech startup Lovevery. While at the company, Lovevery closed a $100 million Series C funding round led by TCG, valuing the startup at $800 million.

Montgomery, who's based in Boise, Idaho, and spends time in New York, went back to venture capital in 2023, joining Collaborative Fund as a partner to focus on next-generation consumer startups. He's backed the teen-focused marketing and data startup Cafeteria.

"Showing initiative and the ability to spot potential will set you apart," he said of people looking to get into venture capital. "This could mean helping startups or writing publicly about your ideas. Build a track record of insights that demonstrate how you think about opportunities."

Chris Morales, Point72 Ventures
Chris Morales is a defense tech partner at Point 72 Ventures.
Chris Morales

Point 72 Ventures

Morales leads Point72 Ventures' defense tech practice, a field he's been passionate about since starting his career as a naval flight officer, wherein he was responsible for operating the weapon systems of fighter aircraft. He served in the Navy for eight years before transitioning into investment banking at Goldman Sachs.

Morales joined Point72 Ventures in 2020 as a vice president and was promoted to partner in April. He opened the firm's first office in Washington, DC, in May to build up Point72's military tech presence. He's led and worked on some hot defense tech deals, including the autonomous-pilot startup Shield AI's $90 million Series C in 2021 — the startup clinched more funding last year at a $2.7 billion valuation — and a 2020 investment into Stoke Space, a reusable-rocket company backed by Bill Gates' Breakthrough Energy Ventures.

Morales led the autonomous-driving-tech startup Overland AI's $10 million seed round in May. He's backed several other defense tech startups that are still in stealth this year.

Mason Murray, New Enterprise Associates
Mason Murray	New Enterprise Associates (NEA)
Mason Murray

New Enterprise Associates (NEA)

Mason Murray joined NEA as a Senior Associate in 2022 and helped form its AI investment thesis. He's been involved in several recent AI bets, including Glacier, Limitless AI, and Twelve Labs. Earlier this year, Twelve Labs raised $50 million in funding from NEA and Nvidia.

Prior to NEA, Murray worked in investing banking at Bank of America.

As for his advice for any aspiring VCs: "VC is multidisciplinary and there's no single path in. My advice would be to assess your operational strengths, areas of expertise, and unique networks. Your recruiting, sourcing, and network-building strategies will be most effective when tailored to where you can deliver near-term value. When you find your sweet spot, lean into it."

Sruthi Ramaswami, Iconiq Growth
Sruthi Ramaswami, Iconiq Growth
Sruthi Ramaswami

Iconiq Growth

Iconiq Growth had only a handful of healthcare investments when Ramaswami joined the firm in 2018. Over the past seven years, she's helped Iconiq establish a presence in the industry with 15 healthcare bets, sourcing and leading deals such as the firm's investments into Benchling, Devoted Health, and Unite Us.

This year, she sourced and closed Iconiq's investment into the medical device startup AcuityMD's $45 million Series B round, and she now sits on the startup's board of directors. Her 15 startup investments are worth $1.5 billion today.

Beyond the firm, Ramaswami works to improve diversity in venture capital as a cofounder of Neythri.org, a community of South Asian professional women, and a founding limited partner of the Neythri Futures Fund, a fund made up primarily of South Asian investors that's focused on backing startups with underrepresented founders, especially South Asian women. Two of that fund's portfolio companies, Cacheflow and Rupa Health, were acquired this year.

Naren Ramaswamy, Alumni Ventures
Naren Ramaswamy 	Alumni Ventures
Naren Ramaswamy

Alumni Ventures

Naren Ramaswamy has been promoted four times over the past two years at Alumni Ventures, moving from associate to now the youngest junior partner at the firm. Ramaswamy helped craft Alumni Ventures' AI thesis and created a data-driven sourcing engine for the form. He sourced and led more than deals across AI, SaaS, and deep tech, including Daydream, Vectara, and Vanilla.

Before his work in Silicon Valley, he was a touring soloist/composer on the Indian bamboo flute under musician Ravi Shankar's school of music. Ramaswamy holds three degrees from Stanford, including bachelor's and master's degrees in engineering and an MBA from Stanford's Graduate School of Business. He also teaches a course at the university on venture capital.

Jordan Segall, Redpoint Ventures
Jordan Segall, Redpoint Ventures
Jordan Segall

Redpoint Ventures

Segall joined Redpoint in 2021, concentrating on SaaS, developer tools, AI, and security startups. He likes to invest in companies early, at either seed or Series A, with checks ranging from $1 million to $30 million.

"I've worked in startups like Palantir, C3.ai, and RelateIQ across engineering, product, and presales and leverage those experiences to help founders on everything from recruiting and interviewing candidates, sourcing key customer leads and helping founders with GTM strategy, and thinking through core strategic initiatives and goal setting/planning," Segall said.

Iris Sun, 500 Global
Iris Sun, 500 Global
Iris Sun

500 Global

Earlier this year, Sun moved from TSVC to 500 Global, where she focuses on data infrastructure, vertical intelligence applications, and cybersecurity startups. Sun invests in pre-seed to Series A rounds, with check sizes ranging from $150,000 to $5 million.

"What truly excites me is finding highly technical founders who deeply understand their domains and are committed to building ambitious global companies that can reshape their industries," Sun said.

Companies she has backed include d-Matrix, which is developing a digital in-memory computing architecture, and Ridge Security, an AI agent platform for security validation.

Christopher Wan, Bessemer Venture Partners
Christopher Wan
Christopher Wan, Bessemer Venture Partners

Bessemer Venture Partners

Wan has been spearheading Bessemer Venture Partners' early-stage deep tech investments, including in quantum computing, defense tech, and AI and machine learning. Wen has worked closely with the firm's AI and defense companies, including Bastille, Lumachain, and ModelCode.ai, Bastille, a company developing hardware and software to provide wireless intrusion security software to the US government, recently raised a $44 million in Series C funding.

Wan also helped lead Bessemer's investment in defense AI startup DEFCON AI's $44 million seed round this year.

Prior to joining Bessemer, Wan was an investor at In-Q-Tel and Tusk Ventures, investing in companies at the intersection of technology and government. While getting his MBA and law degree at Stanford, Wan was part of the Stanford Institute for Human-Centered AI, where he researched and wrote policy reports on artificial intelligence.

Andrea Wang, General Catalyst
Andrea Wang, General Catalyst
Andrea Wang

General Catalyst

Wang joined General Catalyst as a partner in May 2023 to focus on early-stage B2B software and AI investments. In the year and a half since, she's worked on 17 of the VC firm's deals, including General Catalyst's seed investment in Pylon, which raised a $17 million Series A led by Andreessen Horowitz in August.

Before joining General Catalyst, Wang led product growth efforts at the analytics company Amplitude, which now helps her understand the pain points of the enterprise startups she invests in. She's also an angel investor, making bets alongside VC heavy-hitters like Sequoia Capital and Coatue, as well as General Catalyst.

Based out of General Catalyst's San Francisco office, Wang helps cultivate relationships between the firm and founders in the Bay Area, including by working with student organizations at Stanford University to identify top student builders. She recently hosted a speed-dating-style event series meant to help entrepreneurs find cofounders in the community.

Derek Xiao, Menlo Ventures
Derek Xiao, Menlo Ventures
Derek Xiao

Menlo Ventures

Menlo has called Xiao a "driving force" of its investments at the frontier of artificial intelligence. Early last year, he led the diligence process for Anthropic — before it had any revenue and before others saw it as a threat to OpenAI's dominance. His iron grasp on the technicals helped the firm establish a thesis for how enterprises would adopt large language models and allowed it to gain conviction in Anthropic before the opportunity was obvious.

Xiao found further success with an investment in Neon, a serverless-database provider that has since raised from Microsoft and is now seeing rapid adoption from enterprises.

He also led Menlo's thesis work around infrastructure to power the next generation of apps. This led Menlo to lead a $40 million Series B round of funding for Unstructured, a startup that helps enterprises transform unstructured data into formats compatible with large language models.

Before he became an investor, Xiao worked as a consultant at Bain & Company.

Mark Xu, Lightspeed Venture Partners
Mark Zu
Mark Xu

Lightspeed

Xu is a growth investor at Lightspeed, focusing on enterprise software companies raising Series B rounds and beyond. He typically deploys $50 million to $150 million. Xu splits his time between finding new companies and doubling down on existing investments like Wiz, Glean, Grafana, Verkada, and Anduril.

Xu prides himself on connecting companies to the right people.

"I've been fortunate to build individual relationships with a wide variety of people," Xu said. "I love being able to 'activate' my network and share those relationships with the companies I work with."

Yuanling Yuan, SignalFire
Yuanling Yuan, SignalFire
Yuanling Yuan

SignalFire

Yuan, who goes by "YY," came to VC from particularly unconventional beginnings — as a women international master in chess. She landed that title at age 14 and was the top female player in Canada for seven years, leading her to start a nonprofit during her high-school years called Chess in the Library, which has run more than 30 chess programs at public libraries across Canada.

Now, as a partner at SignalFire, Yuan tries to predict several moves ahead in healthcare. She's helped grow SignalFire's healthcare portfolio to 30 startups, including by co-leading the firm's investments into startups like the AI-powered medical coding company CodaMetrix, which SignalFire first backed in 2023 at the time of its $55 million Series A, and Praia Health, which spun out of the health system Providence to land a $20 million Series A in April. She sits on the boards of Praia Health, the medical data annotation platform Centaur Labs, the medication adherence startup Wellth, and the clinical documentation company Health Note.

Before joining SignalFire in 2019, Yuan spent two years at Blackstone working on the firm's emerging-markets team and then evaluating late-stage and IPO investments. She also cofounded the New York Corporate Chess League, which saw Blackstone players face off with teams from top institutions like Goldman, JPMorgan, and Bank of America Merrill Lynch.

Jelena Zec, Citi Ventures
Jelena Zec, Citi Ventures
Jelena Zec

Citi Ventures

In her three years with Citi Ventures, Zec has executed on nearly a dozen investments — more deals than some investors hope to make in twice the time. This year, she led Citi's investments in Wealth.com, an estate-planning company; Finix, a payment processor taking on Stripe; and Norm AI, a company working to automate regulatory compliance.

Zec has spent her career in venture capital and growth investing and now acts as a critical bridge between founders of fintech and wealth companies and large financial institutions that are target customers. Her efforts help startups win enterprise business and ensure Citi has access to startups whose partnerships keep the bank competitive.

Emily Zhao, Salesforce Ventures
Emily Zhao, Salesforce Ventures
Emily Zhao

Salesforce Ventures

Salesforce Ventures has committed $1 billion to invest in new applications for artificial intelligence, and it's counting on Zhao to surface the best and brightest teams for investment. Since she joined the firm in 2022, Zhao, a principal, has played a pivotal role in leading some of its biggest investments, including Anthropic, Hugging Face, RunwayML, Protect AI, and Cohere.

More recently, Zhao sourced and led the latest round in Together AI, a startup that allows businesses to train and deploy their own large language models or an open-source model, and one of the largest investments Salesforce Ventures has made in the genAI category to date.

Before Salesforce Ventures, Zhao started her investment career as an associate in the private equity group at Blackstone, where she focused on corporate buyouts. Her passion for finding and backing exceptional founders led her to switch to earlier-stage investing.

Ivan Zhou, Accel
Ivan Zhou, Accel
Ivan Zhou

Accel

Zhou's arrival at Accel in March felt more like a homecoming than a fresh start. Before he became an investor, Zhou founded and led a social gaming company, Mayhem, that raised money from Accel. In 2021, Niantic, the maker of "Pokémon Go," acquired his startup for an unknown sum and put Zhou in charge of product for its game platform. He built out new social and community features and, on the side, advised early-stage founders in Accel's portfolio.

This past spring, Zhou led Accel's Series A investment in Decagon, a buzzy startup developing virtual agents for customer support. He chased down the team before his official start date with Accel, and the term sheet was signed during his first week on the job.

Read the original article on Business Insider

Many digital health startups are quietly raising down rounds and closing up shop. Here's why.

Stethoscope with "for sale" sign attached
Investors told BI that many healthcare startups are shopping themselves around right now to avoid shutting down.

copyright rhinoneal/Getty Images

  • Hundreds of healthcare startups haven't raised fresh venture funding since 2021.
  • Now, VCs say many digital health startups are cutting their valuations to live another day.
  • Numerous startups are quietly folding, investors said, while others hope to get bought out.

For a brief moment at the beginning of 2024, as healthcare investors broke out their checkbooks after a two-year funding desert and gave new life to a struggling class of startups, it looked like starving health tech founders would be fed once more.

This year's new funding reality hasn't given all of the previous healthcare darlings a seat at the table.

Healthcare startup Forward made headlines this month when the startup abruptly shut down after raising a $100 million Series E in November 2023 for its AI doctor-in-a-box, a bet marked by numerous logistical and financial challenges, Business Insider found.

Many more startups are quietly struggling — cutting their valuations, selling off assets, or closing their doors without any announcement, investors told Business Insider.

While 2021 saw a record-breaking 729 healthcare startup deals, amounting to an eye-popping $29.1 billion raised total, the first three quarters of 2024 only brought in about half of those deals with much smaller check sizes, at $8.2 billion raised through September with 379 deals, per Rock Health.

The dropoff suggests hundreds of startups that nabbed funding during VC's ZIRP period have now been left out to dry. As of mid-November, PitchBook data shows 327 digital health startups that grabbed funding in 2021 but haven't raised since. Not even the AI boom, which has brought back-to-back fundraises for hot healthcare startups like Abridge, can make up for the discrepancy.

Investors told Business Insider that dozens of startups are now raising funding rounds at a valuation lower than their last round, also known as a down round, or hoping to merge with a competitor to extend their lifespans. Others could shut down altogether.

"There are more digital health companies that are selling assets, selling people, or whatever they can," said Greg Yap, a partner at Menlo Ventures. "This is a difficult market. We're definitely not done with companies going out of business."

Same companies, different terms

After healthcare startups raised big rounds in 2021 at high valuations — and then the floor dropped out — plenty of investors threw their startups a lifeline with bridge rounds, meant to give founders a handful of extra cash to get them to their next labeled funding round.

But those firms are done propping up portfolio companies that still aren't succeeding as expected, several healthcare VCs told BI.

As AI startups explode in popularity, Doba Parushev, vice president of CareFirst BlueCross BlueShield's Healthworx Ventures, said some limited partners just want the funds they're backing to focus on new and exciting deals and cut their losses.

"At least for some firms, the LP sentiment is it was a bad vintage. It's done, move on. That's liberating," Parushev said. "I think that's probably driving some behavior around not doing any more internal defensive rounds."

AI hand holding cash.
Some VCs are turning to new AI investments as their existing healthcare portfolios struggle.

Getty Images; Jenny Chang-Rodriguez

Some startups will thus need to adjust their prices to get the chance to raise more capital from either new or existing backers. Alyssa Jaffee, a partner at 7wireVentures, said she's still being pitched some too-expensive deals, with hints of the funding expectations left over from 2021's heyday. But she's seeing more healthcare companies accept the need to take a valuation cut to hit their milestones.

"I would actually hope that more companies said, I'm OK with a down round. We recognize that we were mispriced in the market, and we need to rightsize," she said. "There are expectations from earlier investors who don't want to necessarily take the markdown but may need to take it because that's what's right for the business."

While down rounds are happening at every stage, investors said Series B and C startups may be the most likely to cut their valuations right now since they're more likely to have revenue traction that suggests they're worth continuing to bet on.

Seed and Series A companies, on the other hand, could be more likely to shut down without that traction. Pregnancy and postpartum care startup Ruth Health announced it was closing down in November after failing to find the necessary product-market fit. The company last raised a $2.4 million seed round in 2022.

"Layoffs are awful. Seeking acquisition is humbling. Selling your baby for parts gets demoralizing. The checklist for a wind-down is long," Ruth Health CEO and cofounder Alison Greenberg wrote in a LinkedIn post about the shutdown.

Tie-ups and shut-downs

Not all healthcare shutdowns this year have happened quietly. Healthcare clinic startup Forward made headlines in November by announcing it was closing up shop, a year after raising $100 million to scale its AI-powered kiosks called CarePods. A Business Insider investigation revealed technical and logistical snags in Forward's style-over-substance strategy — like its self-service blood draws not working as expected, and patients getting stuck in the CarePods.

But investors said many more healthcare businesses have shut their doors under the radar this year, especially seed and Series A companies, who have the benefit of fewer eyes on them. This phenomenon hasn't been specific to healthcare — 254 venture-backed startups across all sectors went bankrupt in the first quarter of 2024 alone, according to Carta. And Healthworx's Parushev said he's expecting plenty of healthcare bankruptcies still up ahead.

Forward San Francisco clinic
Forward's San Francisco clinic. The startup said on November 12 that it would shutter all its clinics, effective immediately.

Rob Price/BI

To avoid a shutdown, some startups are looking to combine with a competitor to extend both companies' lifespans. VC firms might move to revitalize two of their portfolio startups at once, as in the case of LetsGetChecked's $525 million acquisition of Truepill. Both startups are backed by Optum Ventures.

Axios reported in August that LetsGetChecked was seeking $150 million in a convertible note to help finance the deal. Galym Imanbayev, a partner at Lightspeed Ventures Partners, said he's seeing a fair amount of similar pitches packaged as "consolidation rounds" rather than down rounds — startups raising more money to enable a merger or acquisition. That's generally a more attractive option to investors than a straightforward down round, he said.

Other startups are choosing to get folded into a competitor without fanfare, Menlo Ventures' Yap said.

"Nobody wants to make a big deal out of a company that didn't quite work out. A lot of that is happening, but if you don't have to announce it, why would you?" he said. "The surviving company, the acquiring company, can just get a little bigger and announce it whenever it makes sense, or not announce it at all."

Truepill cofounders Umar Afridi and Sid Viswanathan
Truepill's cofounders Umar Afridi and Sid Viswanathan.

Courtesy Truepill

The next chapter

Healthcare still has plenty of room for winners. Startups like Hinge Health and Omada Health are expected to test the IPO waters next year, and private equity firms are looking for healthtech companies to scoop up.

Certain areas of healthcare will have to work harder than others to make it to the other side.

While healthcare AI deals have taken center stage this year, virtual care has faltered; telehealth startups nabbed $1.4 billion in VC capital in the first three quarters of this year, compared with $2.8 billion in total last year (and $10.2 billion in 2021), according to PitchBook data. Broadly, healthcare services have fallen out of favor, with clinic startups struggling to deliver returns against capital-intensive models and retailers like Walgreens and Walmart downsizing their healthcare offerings or ditching them altogether.

VCs told BI they're pushing the next generation of healthcare startups for better discipline in balancing growth with profits.

"Hopefully, now people have a more sober view of what it takes to be sustainable, and there'll be a set of companies that may choose to grow a little bit more slowly, but with good unit economics and with EBITDA, with profits," Yap said. "That can give them the opportunity to not be subject to the vagaries of venture capital, private equity, and other people's money."

Read the original article on Business Insider

Forward's leaders are already recruiting for a new startup, just a week after the healthcare company shut down

Adrian Aoun, founder and CEO of Forward
Adrian Aoun, founder and former CEO of Forward

Adrian Aoun

Healthcare startup Forward just closed its doors last week, but its executives are already onto their next venture.

Adrian Aoun, Forward's former CEO, is cofounding a new company alongside the startup's former head of operations, Jonathan Lesser, and its former head of product, design, and engineering, Bali Raghavan, according to messages seen by Business Insider.

Lesser told former Forward employees that Aoun will serve as a cofounder, board member and advisor to the new startup, per the messages.

It's unclear what the startup will focus on as a business or if any of Forward's previous investors will be involved in the new venture. Forward raised over $650 million from top investors like Khosla Ventures, Softbank, and Salesforce's Marc Benioff.

Aoun, Lesser, and Raghavan didn't respond to requests for comment from Business Insider.

It's an ultra-quick turnaround from Forward's leaders after the startup announced on November 13 that it would immediately shutter its more than a dozen locations and lay off its nearly 200 employees.

Launched in 2017, Forward sought to reimagine healthcare with ultra-modern clinics and grabbed a $100 million Series E round in November 2023 to power its AI-powered healthcare kiosks, called CarePods.

But a series of logistical and technical challenges — from the CarePods' self-service blood draws not working as expected, to patients getting stuck inside the large metal boxes — hindered Forward's CarePods rollout, Business Insider found. And patients didn't flock to the CarePods as Forward hoped, according to former employees.

On a Friday episode of The Information's More or Less podcast, Aoun said he's already hearing interest from Forward's investors to back his next venture.

"On Tuesday morning, I was like, I've decided, I'm doing nothing for six months to a year. I need a break, I'm licking my wounds, this really f—ing sucks," he said. But that day, he said, one of Forward's biggest investors called him to ask, "So what are you doing next, and can I cut you a term sheet?"

"We just burned not quite half a billion dollars on an idea. And a lot of people's reaction is, what are you doing next? Let's do it again," he continued. "What sort of special ass culture did we create in Silicon Valley where this is reality? This is absurd."

Got a tip on Forward? Contact Rebecca Torrence via encrypted messaging app Signal (+1 423-987-0320), or email [email protected] and contact Rob Price via encrypted messaging app Signal (+1 650-636-6268), email ([email protected] or [email protected]).

Read the original article on Business Insider

❌